

S-Adenosylmethionine (SAM) and S-Adenosylhomocysteine (SAH) Related Reagents and their Applications

Sheryl Hao, MD., Ph.D.

Arthus Biosystems
2600 Hilltop Drive
Richmond, CA 94806

Email: sheryl.hao@arthusbio.com


Web: <http://www.arthusbio.com>





Respond to challenge, make it possible

**Part 1: Understand S-adenosylmethionine (SAM),
S-adenosylhomocystein (SAH), Methylation Index
and Methionine Cycle**

S-adenosylmethionine (SAM) is the key molecule in methionine cycle. It plays essential roles in the synthesis and metabolism of nucleic acids, proteins as well as maintaining the mobility of cytoplasmic membranes.



SAM is an intrinsically unstable molecule with MW 398.44, and its optical density maximum of 258-260 nm is not a distinguished absorption, the determination of its concentration in various biological fluids and tissues has always been a challenging task.



S-Adenosylmethionine (AdoMet) is metabolized through (a) transfer of its methyl group to a variety of methyl acceptors, (b) decarboxylation followed by aminopropylation leading to polyamine synthesis, and (c) cleavage of the bond between the sulfur atom and carbon 4 of the amino acid chain, resulting in formation of methylthioadenosine and homoserine thiolactone.

About two-thirds of the metabolized compound being utilized via transmethylation and cleavage to methylthioadenosine and one-third via decarboxylation.

A better precursor than methionine both in creatine formation and in the utilization of the sulfur atom in transsulfuration reactions.

Important roles of SAM in birth defects, cardiovascular disease, tumors, liver diseases, mood problems, diabetes, digestive diseases, chronic fatigue, geriatric diseases such as Alzheimer's, Parkinson's Disease, etc.

SAH and homocysteine are closely related to cardiovascular diseases. SAH is considered as a disease marker.

Spermidine serves vital roles in **cell survival**. Spermidine synchronizes an array of biological processes (such as Ca^{2+} , Na^{+} , K^{+} -ATPase) thus maintaining **membrane** potential and controlling intracellular pH and volume. Spermidine regulates biological processes, such as Ca^{2+} influx by glutamatergic **N-methyl-d-aspartate** receptor (NMDA receptor), which has been associated with **nitric oxide synthase** (NOS) and cGMP/PKG pathway activation and a decrease of Na^{+} , K^{+} -ATPase activity in cerebral cortex synaptosomes.

Spermidine is a **longevity** agent due to its impact on chromatin-mediated regulation of gene expression.

Spermine is a **polyamine** involved in **cellular metabolism** found in all **eukaryotic cells**. The precursor for synthesis of spermine is the amino acid **ornithine**. It is found in a wide variety of organisms and tissues and is an essential **growth factor** in some **bacteria**. It is found as a polycation at physiological pH. Spermine is associated with **nucleic acids** and is thought to **stabilize helical structure**, in particular, in **viruses**.

How to measure SAM and SAH?

Since SAM is an intrinsically unstable molecule, the determination of its concentration in various biological fluids and tissues has been challenging.

Currently known: HPLC, LC-MS/MS

Now adding: Immunoassay -- A simple, convenient method that does not require costly instrumentation

Given high quality anti-SAM and anti-SAH antibodies, immunoassays are ideal for:

- (1) Sensitive: about 2nM SAM and 15nM SAH with ELISA.
- (2) Highly specific: we know what we are looking at.
- (3) Quick and convenient
- (4) No need of special equipment
- (5) Potential for development IVD or POCT products with immunological methods

Why using immunoassays for SAM and SAH?

HPLC is replaced by MS due to its inaccurate, poor sensitivity and hard to separate SAM and SAH.

Limitations and problems of the prevailing LC-MS/MS :


- (1) No consideration of biological activity-relevance of the metabolites it detects. It may not be accurate and complete from the biological perspectives.
- (2) The chemical methods can only detect free form of SAM or SAH excluding any form of SAM or SAH associated with other bio-molecules.
- (3) Just because LC-MS/MS cannot detect from a sample the SAM molecules that falls within that narrow molecular weight specification may not always mean SAM has been totally degraded, disappeared and non-functioning.
- (4) The SAM standard used in training LC-MS/MS are not exactly the same as the SAM in living cells, yet in technology like LC-MS/MS, the exact same molecule as the one to be measured is required as the standard.
- (5) **Fatal issue:** Doubt of GC-MS and LC-MS analytical methods that may not accurately measure metabolites due to unwanted changes caused by manipulation processes including sample extraction, preprocessing and during the lengthy measurement cycle, which involve high temperature with inorganic solvent that may change the metabolites to be measured. See link below:

<http://cen.acs.org/articles/93/i42/Heated-Dispute-Over-Analytical-Method.html>


Part 2: Characterization and Uses of anti-SAM and anti-SAH Antibodies

SAM Biosynthesized from Methionine and ATP

Dose-dependent competition was measured as a sample was added to the cELISA. Any SAM from a sample competes with the coated SAM haptan to bind RP-conjugated anti-SAM antibody. The sample is the product of the following reaction: MAT was added to Met and ATP in a proper buffer at 37°C.




The following has been observed in all anti-SAM antibodies we have. It indicates that all anti-SAM antibodies can specifically binds physiologically produced SAM





Mouse anti-SAM Cross Reactions to Analogs



- S-Adenosylmethionine: 100%
- S-Adenosylhomocysteine: <1%
- Adenosine: <1%
- L-Methionine: <1%
- Methylthioadenosine (MTA): <1%
- ADP < 1%
- ATP < 1%




SAM: NAT (Adjacent Normal Tissue) breast and liver, ubiquitous in cytoplasm




SAH: NAT liver, nuclear and cytoplasm



Adjacent normal lung – M56, SAM




Squamous cell carcinoma (T2N0M0, I) – M56, SAM




Adjacent normal lung NAT – M39, SAM




Adenocarcinoma (T2N0M0, II) – M39, SAM




Adjacent normal kidney – M54, SAM



Kidney clear cell carcinoma (T1N0M0, I) – M54, SAM



Adjacent normal cerebrum – M52, SAM



Astrocytoma – M18, SAM






Figure 2 Immunohistochemistry staining performed using MA00202 with benign liver tissue adjacent to carcinoma. Brown areas indicated strong positive staining in cytoplasm (X400).




Figure 3 The immunohistochemical staining is performed for the same sample as in Figure 2 with liver cancer tissue. Cytoplasm showed background staining (further dilution beyond 1:200 is required) with Ma00202 (X400).

Specificity of monoclonal anti-SAM antibody 84-3




Figure 4 FCM analysis control. Normal liver cells L02 and carcinoma cells Hep G2 were stained with the buffer without any antibody.




Figure 5 FCM results from normal liver cell line L02 and hepatocyte carcinoma cell line Hep G2 stained with anti-SAM monoclonal antibody from clone 118-6. Average fluorescence signal in Hep G2 cells was reduced compared to that in L02 cells, indicating SAM level is reduced during carcinogenesis.

Proof of concept: anti-SAM antibodies can be used in FCM. Not meant for quantification

Proof of concept: Anti-SAM antibody 84-3 stains better than 118-6 in FCM




Figure 4 FCM analysis control. Normal liver cells L02 and carcinoma cells Hep G2 were stained with the buffer without any antibody.




Figure 5 FCM results from normal liver cell line L02 and hepatocyte carcinoma cell line Hep G2 stained with anti-SAM monoclonal antibody from clone 84-3. Average fluorescence signal in Hep G2 cells was reduced compared to that in L02 cells, indicating SAM level is reduced during carcinogenesis.





Figure 2 Immunohistochemistry staining performed using PA00201 (1:20) with benign lung tissue adjacent to carcinoma. Brown areas indicated strong positive staining in cytoplasm and nuclei (X400).




Figure 3 The immunohistochemical staining was performed for the same sample as in Figure 2 with lung cancer tissue. Cytoplasm and nucleus showed negative staining with PA00201 at 1:20 dilution (X400).

Polyclonal antibody against SAM

Functional Affinity – Mouse anti-SAM

For the reaction: $Ab + Ag = AbAg$

the rate of formation of the $AbAg$ complex $r_f = k_{forward}[Ab][Ag]$

the rate at which it breaks down $r_b = k_{backward}[AbAg]$

$[Ag]$: Concentration of antigen; $[Ab]$: concentration of antibody; $[AbAg]$: concentration of $AbAg$ complex. The rate constants $k_{forward}$ and $k_{backward}$ depends on temperature, pH and other conditions.

At equilibrium, $r_f = r_b$

The equilibrium or affinity constant K_a or K is defined from the equation:

$$K = \frac{k_{forward}}{k_{backward}} = \frac{[AbAg]}{[Ab][Ag]}$$

Dilution	Monoclonal anti-SAM 84-3 PLL-SAM	
	0.05ug/ml	0.1ug/ml
1000	3.3764	4.7244
2000	3.2469	4.5207
4000	3.1591	4.5844
8000	2.9176	4.3432
16000	2.6605	4.2673
32000	2.1978	3.7642
64000	1.6954	3.1152
128000	1.2151	2.3332

At 0.1ug/ml, half the maximum OD was seen at 1:130000. $[Ab] = (1\text{mg/ml}/160,000\text{g/mol})/130000 = 4.807 \times 10^{-11}$.

at 0.05ug/ml, half the maximum OD was seen at 1:7000. $[Ab] = (1\text{mg/ml}/160,000\text{g/mol})/7000 = 8.92 \times 10^{-11}$.

$n = (0.1\text{ug/ml})/(0.05\text{ug/ml}) = 2$

$K_a = (n-1)/2 * (n[Ab] - [Ab]t) = 7.29 \times 10^{10} \text{ L/mol} = 1.37 \times 10^{-11} \text{ M}$

Sensitivity - Mouse anti-SAM

118-6

The data below showed the minimum detection limit, which was calculated by OD (when antigen = 0) - 2 x Standard deviation = 1.2683 - 2 x 0.0439 = 1.1805, was about 2.6nM.

SAM (nM)	OD450	OD450	OD450	Mean	SD
Blank	0.0556	0.0808	0.0616	0.0660	0.0131
0	1.2189	1.2831	1.3030	1.2683	0.0439
6.25	1.110	1.0648	0.9757	1.0502	0.0683
12.5	0.885	0.8004	0.8737	0.8530	0.0459
25	0.6252	0.6435	0.6108	0.6265	0.0164
50	0.3838	0.3995	0.3782	0.3872	0.0110
Sensitivity	2.6 nM				

84-3

SAM standard (nM)	PLL-aza-SAM								
	0.2µg/ml			0.15µg/ml			0.1µg/ml		
Blank	0.0498	0.056	0.0522	0.0476	0.0471	0.0482	0.0754	0.0515	0.0476
0	1.4709	1.4344	1.4072	1.215	1.2484	1.2651	1.0844	1.1231	1.0633
6.25	1.365	1.3257	1.2673	1.0789	1.0734	1.0842	0.879	0.9122	0.8995
25	1.1769	1.1498	1.1015	0.8231	0.844	0.8334	0.6209	0.6561	0.6679
50	1.0230	0.9856	0.9577	0.6428	0.6362	0.6005	0.4517	0.4555	0.5187
100	0.7687	0.7532	0.7292	0.4292	0.4203	0.4427	0.3036	0.3103	0.3071
Sensitivity	3.0nM			1.7nM			1.6nM		

Mouse anti-SAH Cross Reactions to Analogs

S-Adenosylhomocysteine: 100%
 S-Adenosylmethionine: 1.5 – 2.5%
 Adenosine: L-Methionine: <1%
 Adenosine Triphosphate: ~1.29%
 Homocysteine: <1%
 L-Cysteine: <1%
 Glutathione: <1%
 L-Cystathionine: <1%
 Methythioadenosine (MTA): <5%
 ADP (adenosine diphosphate): < 1%
 ATP (adenosine triphosphate): < 1%




Figure 1 Competitive ELISA using anti-S-Adenosylmethionine monoclonal antibody [301-1] (Ma00301)

Functional Affinity – Mouse anti-SAH (301-1)

Dilution from 2.31mg/ml	BSA-SAH 0.5µg/ml	BSA-SAH 0.25µg/ml
500	4.7390	4.3120
1000	4.9049	4.0379
2000	4.5869	3.7715
4000	4.1598	3.5240
8000	3.2419	2.7578
16000	2.3605	2.0027
32000	1.3452	1.2803
64000	0.9372	0.8287

At 0.5ug/ml, half the maximum OD was seen at 1:16000. $[Ab] = (2.31\text{mg/ml}/160,000\text{g/mol})/16000 = 9.023 \times 10^{-10}$
 at 0.25ug/ml, half the maximum OD was seen at 1:12000. $[Ab]_t = (2.31\text{mg/ml}/160,000\text{g/mol})/12000 = 1.203 \times 10^{-9}\text{M}$.
 $n = (0.5\text{ug/ml})/(0.25\text{ug/ml}) = 2$

$$K_a = (n-1)/2 * (n[Ab] - [Ab]_t) = 8.32 \times 10^8 \text{ L/mol} = 1.2 \times 10^{-9} \text{ M}$$

Functional Affinity – Mouse anti-SAH (844-1)

Dilution from 1mg/ml	BSA-SAH 0.2µg/ml	BSA-SAH 0.4µg/ml
1000	2.94505	3.79275
2000	2.71675	3.6411
4000	2.51445	3.5291
8000	2.34215	3.33185
16000	2.0829	3.07145
32000	1.74925	2.5685
64000	1.28195	1.8321
128000	0.9474	1.3221

At 0.4ug/ml, half the maximum OD was seen at 1:64620. $[Ab] =$

$$(1\text{mg/ml}/160,000\text{g/mol})/64620 = 9.67 \times 10^{-11} \text{ M.}$$

at 0.2ug/ml, half the maximum OD was seen at 1:51000. $[Ab] =$

$$(1\text{mg/ml}/160,000\text{g/mol})/51000 = 1.225 \times 10^{-10} \text{ M.}$$

$$n = (0.5\text{ug/ml})/(0.25\text{ug/ml}) = 2$$

$$K_a = (n-1)/2 * (n[Ab] - [Ab]_t) = 7.053 \times 10^9 \text{ L/mol}$$

Functional Affinity – Mouse anti-SAH (839-6)

Dilution from 1mg/ml	BSA-SAH 0.1µg/ml	BSA-SAH 0.2µg/ml
4000	1.9792	2.8577
8000	1.8630	2.7525
16000	1.7730	2.54815
32000	1.5913	2.2704
64000	1.3102	1.7912
128000	0.9864	1.2551
256000	0.6384	0.82805
512000	0.4205	0.5177

At 0.2ug/ml, half the maximum OD was seen at 1:110400. $[Ab] =$

$$(1\text{mg/ml}/160,000\text{g/mol})/110400 = 5.66 \times 10^{-11} \text{ M.}$$

at 0.1ug/ml, half the maximum OD was seen at 1:137500. $[Ab] =$

$$(1\text{mg/ml}/160,000\text{g/mol})/137500 = 4.545 \times 10^{-11} \text{ M.}$$

$$n = (0.5\text{ug/ml})/(0.25\text{ug/ml}) = 2$$


$$K_a = (n-1)/2 * (n[Ab] - [Ab]_t) = 7.38 \times 10^9 \text{ L/mol}$$

Sensitivity - Mouse anti-SAH


The data showed the minimum detection limit, which was calculated by OD (when SAH = 0) – 2 x Standard deviation = 0.8697 – 2 x 0.033747 = 0.8022, was below 15.625nM.

SAH (nM)	OD450	OD450	OD450	Mean	Stdev	Inhibition (%)
250	0.4116	0.4426	0.442	0.4321	0.017727	50.32%
125	0.5421	0.6358	0.5372	0.5717	0.055566	34.26%
62.5	0.6055	0.7115	0.6444	0.6538	0.053622	24.82%
31.25	0.7285	0.8199	0.7545	0.7676	0.047094	11.74%
15.625	0.8045	0.8273	0.7975	0.8098	0.015582	6.88%
7.8125	0.7602	0.8113	0.7708	0.7808	0.026969	10.22%
3.90625	0.7722	0.9144	0.7786	0.8217	0.080315	55.52%
0	0.877	0.8992	0.8329	0.8697	0.033747	0%


Adjacent normal breast – F46, SAH




Invasive duct carcinoma (T2N1M0, IIb, G1) – F58, SAH



Invasive duct carcinoma (T4N1M0, IIIb, G2) – F50, SAH



Invasive duct carcinoma (T2N1M0, IIb, G3) – F56, SAH







Part 3: Methionine Adenosyltransferase (MAT) Activity Assay


MAT Activity Assay kit is used to study MAT activity regulated by methionine (Met) and S-nitrosoglutathione (GSNO).

Except for parasites that rely on host for living, cells from all organisms have methionine adenosyltransferase (MAT, EC2.5.1.6). MAT genes have been found to be exceptionally conserved throughout evolution. It was reported that there is 59% homology between human and *E. coli* MAT gene sequences. In mammals, three forms or isozymes of MAT have been identified that are encoded by three MAT genes. The MAT1a gene encodes $\alpha 1$ catalytic subunit. MAT-I is a tetramer of $\alpha 1$ subunits and MAT-III a dimer of the same subunits. Both MAT-I and MAT-III are present in adult liver cells. MAT-II is a heterotetramer formed by MAT2a encoding the catalytic subunit of $\alpha 2$ and MAT2b gene encoding regulatory β subunit, present in cells other than liver, embryonic liver and hepatoma cells.


Regulation of MAT activity by methionine. L02 (expresses MAT1a) and HepG2 (expresses MAT2a and MAT2b) cells are good models to study the two types of MAT. **MAT-I/III is stimulated by Met to cope with high Met diet and inhibited by GSNO (S-nitrosoglutathione) which is a NO donor and critical signal in response to injury.** Like Reactive Oxygen Species (ROS), GSNO as a Reactive Nitrogen Species (RNS) is a free radical that imposes damages to cells, proteins and DNA. However, **MAT-II is inhibited by Met and has no response to GSNO.** All types of MAT catalyze SAM synthesis similarly.







Regulation of MAT Activities by Met and GSNO in LO2 and HepG2 Cells



Part 4: Products

www.arthusbio.com

Methylation

SAM $\xrightarrow{\text{CH}_3}$ SAH

DNA, RNA, proteins, phospholipids, hormones, neurotransmitters, ...

Arthus BIOSYSTEMS

Respond to challenge, make it possible

Learn more at www.arthusbio.com

**Streamline Biotech Research Offering
New Tools to Measure S-Adenosylmethionine
(SAM) and Methylation Index**



Respond to challenge, make it possible

Streamline Biotech Research New Tools for S-Adenosylmethionine and Methylation Index



Arthus Biosystems
Tel: +1-510-846-1804
Email: info@arthusbio.com
Web: www.arthusbio.com

**Fast, easy and convenient way
of measuring methylation index is possible**

Stabilized SAM and SAH antigens and antigen conjugates

Aza-SAM a/b

Product name	Aza-SAM, Aza-SAM a/b
Catalog Number	AST00201, AST00201-1, AST00201-200
Chemical name	5'-N-Methyl, 5'-N-butyl-5'-deoxyadenosine, or 5'-[(3-carboxypropyl)methylamino]-5'-deoxy-adenosine

PLL-aza-SAM a/b

Product name	PLL-aza-SAM a/b
Catalog Number	ACT00201-5/10
Description	Poly-lysine was conjugated to S-adenosylmethionine analog Aza-SAM

BSA-aza-SAM a/b

Product name	BSA-aza-SAM a/b
Catalog Number	ACT00204-5/10
Description	Bovine serum albumin (BSA) was conjugated to the S-adenosylmethionine analog Aza-SAM

SAH-Na

Product name	SAH-Na
Catalog Number	AST00301-1
Chemical name	S-Adenosylhomocysteine sodium salt
Description	SAH-Na was synthesized by adding sodium to the carboxyl group of S-adenosylhomocysteine.

BSA-SAH

Product name	BSA-SAH
Catalog Number	ACT00301-50
Description	Bovine serum albumin (BSA) was conjugated to S-adenosylhomocysteine (SAH).



Biotin-conjugated SAH and Digoxin-conjugated SAH

Dig-6C-SAH 1a/b/c

Product name	Dig-6C-SAH 1 a/b/c
Catalog Number	ACT00304-25/50/100
Description	Digoxin-conjugated S-adenosylhomocysteine: Digoxin is conjugated to NH ₂ of SAH through 6-bromocaproic acid.

Bio-12CN-SAH 1a/b/c

Product name	Bio-12CN-SAH 1a/b/c
Catalog Number	ACT00305-10/50/100
Description	Biotin is conjugated with S-adenosylhomocysteine through a 10-carbon and 2-nitrogen linker.





Biotin-conjugated SAM and aza-SAM

Bio-6C-SAM 1a/b

Product name	Bio-6C-SAM 1a/b
Catalog Number	ACT00203-50/100
Description	Biotin-conjugated S-adenosylmethionine:

Bio-12CN-aza-SAM 1a/b/c

Product name	Bio-12CN-aza-SAM 1a/b/c
Catalog Number	ACT00206-10/50/100
Description	Biotin is conjugated with aza-SAM through a 10-carbon and 2-nitrogen linker.





Mouse anti-SAM 1a/b

Product name	Mouse anti-SAM 1a/b
Catalog Number	MA00201-50/100
Description	Mouse monoclonal antibody to S-Adenosylmethionine [118-6]
Specificity	Dosage-dependent competition was detected as a sample was added to a cELISA (Any SAM from a sample competes with the coated SAM heptan to bind HRP-conjugated antibody 118-6). The sample is the product of the following biochemical reaction: Methionine Adenosyltransferase (MAT) was added to methionine and adenosine triphosphate under an appropriate buffer at 37°C. It indicates that antibody 118-6 specifically binds physiologically produced SAM.
Cross Reaction	MA00201 shows the following reactivity with related compounds: S-Adenosylmethionine: 100%, S-Adenosylhomocysteine: < 1%, Adenosine: < 1%, L-Methionine: < 1%, Methythioadenosine (MTA) : < 1%, ADP (adenosine diphosphate) < 1%, ATP (adenosine triphosphate) < 1%
Immunogen	S-Adenosylmethionine analog conjugated to KLH

Properties

Form	Liquid
Storage instructions	Store at 4°C, -20°C for long term storage
Storage buffer	PBS 10mM pH7.4 (NaCl 150mM), Sodium azide 0.02%, BSA 10mg/ml or PBS 10mM pH7.4 (NaCl 150mM), Sodium azide 0.02%, Glycerol 50%, BSA 10mg/ml
Purity	>95% Purified from mouse ascites fluid by affinity chromatography
Clonality	Monoclonal
Clone number	118-6
Immunoglobulin isotype	IgG2b
Affinity	$K_a = 5.75 \times 10^9 \text{L/mol}$ ($1.74 \times 10^{-10} \text{M}$)
Research Areas	Methylation of biomolecules (DNA, RNA, proteins, hormones, neurotransmitters, etc.) One-carbon metabolism Signal Transduction



Mouse anti-SAH 1a/b

Product name	Mouse anti-SAH 1a/b
Catalog Number	MA00301-50/100
Description	Mouse monoclonal antibody against S-Adenosylhomocysteine [301-1]
Specificity	MA00301 shows the following reactivities with related compounds: S-Adenosylhomocysteine: 100%, S-Adenosylmethionine: ~1.5%, Adenosine: <1 %, Homocysteine: < 1%, L-Cysteine: < 1%, Glutathione: < 1%, L-Cystathionine: < 1%, Methythioadenosine (MTA): < 5%, ADP (adenosine diphosphate): < 1%, ATP (adenosine triphosphate): < 1%.
Immunogen	S-Adenosylhomocysteine conjugated to BSA

Properties

Form	Liquid
Storage instructions	Store at 4°C, -20°C for long term storage
Storage buffer	PBS 10mM pH7.4 (NaCl 150mM), Sodium azide 0.02%, BSA 10mg/ml or PBS 10mM pH7.4 (NaCl 150mM), Sodium azide 0.02%, Glycerol 50%, BSA 10mg/ml
Purity	>95% Purified from mouse ascites fluid by affinity chromatography
Clonality	Monoclonal
Clone number	301-1
Immunoglobulin isotype	IgG3
Affinity	$K_a = 2.778 \times 10^8 \text{L/mol}$ ($3.60 \times 10^{-9} \text{M}$)
Research Areas	Methylation of biomolecules (DNA, RNA, proteins, hormones, neurotransmitters, etc.) One-carbon metabolism Signal Transduction

S-Adenosyl-L-Methionine (SAM) ELISA Kit (For Plasma, Serum or Tissue Samples)

Packaging size

96 tests

S-Adenosyl-L-Methionine (SAM) ELISA Kit

Detection range

30 nM – 960 nM

Packaging size

96 tests

Detection range

15 nM – 480 nM




Figure 1 Standard curve Lot#421212 denotes the lot number of HRP-anti-SAM (clone 118-6) that was used at the different dilution shown above. LOGIT = $\ln(A/A_{50}) / (1 - A/A_{50})$



S-Adenosyl-L-Homocysteine (SAH) ELISA Kit (For Plasma, Serum or Tissue Samples)

Packaging size

96 tests

S-Adenosyl-L-Homocysteine (SAH) ELISA Kit

Detection range

15.625 nM – 1000 nM

Packaging size

96 tests

Detection range

15.625 nM – 1000 nM





Figure 1 Standard curve in competitive ELISA with SAH standard from this kit
LOGIT = $\ln(A/A_{50}) / (1 - A/A_{50})$



Methionine Adenosyltransferase (MAT) Activity Assay Kit



The first immunoassay kit to measure MAT activity accurately, conveniently and quickly

Enzymatic activity of MAT is critical in regulating the level of SAM and plays critical roles in methionine cycle and epigenetic study.

- ◆ Highly conserved MAT isoenzymes throughout evolution: MAT-I/III encoded by MAT1a gene and MAT-II encoded by MAT2a and MAT2b genes.
- ◆ MAT-II is important for cell proliferation
- ◆ SAM depleted animals show tissue injuries, necrosis and inflammatory infiltration
- ◆ Epigenetic regulation of MAT can be used as hepatocellular carcinoma therapy


S-Adenosylmethionine (SAM) Quantitative Test Strip (Immunofluorescence Chromatography)

Product Name


S-adenosylmethionine (SAM) Quantitative Test Strip (Immunofluorescence Chromatography)

Packaging

General packaging specifications: > 30 tests/pack.



S-Adenosylhomocysteine (SAH) Quantitative Test Strip (Immunofluorescence Chromatography)




**Part 5: Use SAM and SAH ELISA Kits in
Human Plasma/Serum Samples**

Importance of measuring SAM and Methylation Index (MI = SAM/SAH)

1. Biomarker and therapeutics for neurodegenerative diseases such as dementia, Parkinson's disease, amyotrophic lateral sclerosis (ALS), etc.
2. Serum SAM level for diagnosis of *Peumoncystis Carinii Pneumonia* (PCP) arising from immune compromised conditions.
3. Liver and bile duct diseases
4. Cancers
5. Nutritional imbalance such as folate and/or cobalamin deficiency
6. Congenital diseases such as Down syndrome and congenital heart diseases
7. Monitored treatment for depression, osteoarthritis and liver disorders with SAM-e

1. Serum Samples from 81 Normal Subjects and 99 Liver Diseases



Mean = 386.66 ± 216.20 nM


Mean = 217.30 ± 152.74 nM

MI = 3.75 ± 5.0 (0.1 – 9.9)

Normal SAM levels from 81 human sera are age and gender-dependent.

The younger the age, the higher the level of SAM. SAM level in age group younger than 30 is significantly higher than those from all other age groups. ($p < 0.05$)

SAM level is generally higher in females than males.



ANOVA results

Dataset	Response Variable	Explanatory Variable	p-value	Significance
Healthy	SAM	Age Group	0.03437	**
Healthy	SAH	Age Group	0.4964	
Healthy	MI	Age Group	0.1058	
Healthy	SAM	Gender	0.05115	*
Healthy	SAH	Gender	0.584	
Healthy	MI	Gender	0.8752	

Based on the ANOVA table, we see that Age Group is a significant factor with respect to SAM levels in healthy patients. So we will do pairwise t-tests for each pair of levels of Age Group.

Healthy sera

Age Group 1	Age Group 2	p-value	Significance
20-30	31-40	0.01728	* *
20-30	41-50	0.03793	* *
20-30	51-80	0.005682	* *
31-40	41-50	0.7461	
31-40	51-80	0.7815	
41-50	51-80	0.9081	

So clearly, by the pairwise t-test results, the SAM levels for the healthy patients aged 20-30 are statistically significant from those of the other age groups. And, looking at the plot, of mean SAM levels of healthy patients by Age Group, we see that the SAM levels of healthy patients aged 20-30 are significantly higher than those of the other age groups.

After doing a pairwise t-test for SAM levels of healthy patients by gender, we get a p-value of 0.05117 (note that this is approximately equal to the p-value we got from ANOVA) which is statistically significant at an $\alpha = 0.1$ level. The mean of the female SAM levels is 433.9628 and the mean of the male SAM levels is 340.5072 which means the SAM levels for healthy females are significantly higher than those of healthy males.


ANOVA Analysis of SAM, SAH and MI on 81 Healthy Subjects and 99 Liver Diseases

Dataset	Response Variable	Explanatory Variable	p-value	Significance
Healthy	SAM	Age Group	0.03437	* *
Healthy	SAH	Age Group	0.4964	
Healthy	MI	Age Group	0.1058	
Healthy	SAM	Gender	0.05115	*
Healthy	SAH	Gender	0.584	
Healthy	MI	Gender	0.8752	
Diseased	SAM	Age Group	0.9045	
Diseased	SAM	Gender	0.87	
Diseased	SAM	Diagnosis	0.2694	

SAM Levels in Diagnosis of Liver Diseases

Group	Case No.	SAM (nM)		SAM=120nM Cutoff		SAM=240nM Cutoff	
		Average	Standard Deviation	Detected Number	Detection Rate (%)	Detected Number	Detection Rate (%)
Normal	81	386.66	216.20	3	3.70	25	30.86
Hepatitis	46	101.42	83.12	37	80.43	44	95.65
Carcinoma	14	104.96	82.63	10	71.43	13	92.86
Cirrhosis	20	92.95	62.41	17	85.00	19	95.00
Liver failure	19	66.46	29.77	19	100	19	100

SAM level in liver diseases (99 cases) by age and gender.



Methylation Index and Cancers

Response Variable	Case #	Mean	p-value	Significance
SAM(LiverCancer)	23	278.0652	0.03451	**
SAH(LiverCancer)	23	293.35	0.3288	
MI(LiverCancer)	23	1.562109	0.1131	
SAM(LungCancer)	75	262.5039	0.001248	***
SAH(LungCancer)	75	326.9877	0.007807	***
MI(LungCancer)	75	0.9710702	3.674e-06	****
SAM(OtherCancer)	76	283.3233	0.00116	***
SAH(OtherCancer)	76	394.7301	5.612e-06	****
MI(OtherCancer)	76	0.8156412	8.123e-09	****

- * represents significance at significance level = 0.1
- ** represents significance at significance level = 0.05
- *** represents significance at significance level = 0.01
- **** represents significance at significance level = 0.001

2. Lung Cancer : 80_

t test (Lung cancer vs Normal)

Response Variable	Mean	p-value	Significance
SAM	137.6983	9.595e-16	****
SAH	462.522	1.028e-10	****
MI	0.3840688	1.079e-12	****

3. Methylation Index and Other Diseases >> (next)

Response Variable	Case #	Mean	p-value	Significance
SAM(Cerebral_hemorrhage)	48	357.9406	0.4365	
SAH(Cerebral_hemorrhage)		353.175	0.001237	***
MI(Cerebral_hemorrhage)		1.148035	2.308e-05	****
SAM(Diabetes)	43	262.3474	0.001136	***
SAH(Diabetes)		372.0686	0.003831	***
MI(Diabetes)		0.8619158	9.2e-08	****
SAM(HBP)	22	288.3645	0.0389	**
SAH(HBP)		358.1118	0.01378	**
MI(HBP)		0.9178064	3.929e-07	****
SAM(Heart_diseases)	51	315.962	0.07938	**
SAH(Heart_diseases)		440.9451	5.945e-07	****
MI(Heart_diseases)		0.7822701	5.609e-09	****
SAM(Inflammation)	35	223.732	3.052e-06	****
SAH(Inflammation)		292.012	0.2051	
MI(Inflammation)		0.8193137	1.905e-08	****
SAM(Kidney_diseases)	26	307.6073	0.1077	
SAH(Kidney_diseases)		497.1204	7.761e-06	****
MI(Kidney_diseases)		0.6976807	3.692e-09	****
SAM(Liver_diseases)	30	356.3407	0.5037	
SAH(Liver_diseases)		444.0027	1.22e-06	****
MI(Liver_diseases)		0.8921861	2.717e-07	****
SAM(Pulmonary_diseases)	36	393.3392	0.8827	
SAH(Pulmonary_diseases)		486.5144	4.24e-08	****
MI(Pulmonary_diseases)		0.7916811	5.271e-09	****

4. Methylation Index and Brain Disorders

Diseases	Case #	Response Variable	Mean	p-value	Significance
Cerebral hemorrhage	20	SAM	415.4277	0.6064	
Cerebral hemorrhage	20	SAH	363.3671	0.03015	**
Cerebral hemorrhage	20	MI	1.163449	2.027e-05	****
Depression	10	SAM	337.385	0.3531	
Depression	10	SAH	442.379	0.01176	**
Depression	10	MI	0.87051	4.806e-06	****
Parkinson's Disease	10	SAM	285.5726	0.07684	***
Parkinson's Disease	10	SAH	794.5792	0.06972	****
Parkinson's Disease	10	MI	0.74988	7.18e-06	****

5. Random Study - annual checkup of a group of people. Disease: 271 Healthy: 303

Diabetes + HBP Diabetes	19 (18 + 1)
High Blood Pressure (HBP)	41
Heart diseases	29
Inflammation + Gall Bladder diseases	16 (9 + 7)
Kidney diseases	15
Liver diseases + HBP Liver diseases	76 (75 + 1)
Others: Cerebral hemorrhage + Prostatic hypertrophy + Pulmonary diseases	22 (9 + 7 + 6)
Sub-healthy	53

Results of Student t-tests between healthy and each disease group

Response Variable	Mean	p-value	Significance
SAM (Healthy)	526.3652 (healthy 611.5152)	0.0001353	****
SAH (Healthy)	575.2576 (healthy 622.8114)	0.01636	**
MI (Healthy)	1.220361 (healthy 1.60444)	0.08857	*

Response Variable	Mean	p-value	Significance
SAM(Diabetes)	627.8685	0.7581	
SAH(Diabetes)	630.7851	0.8923	
MI(Diabetes)	2.212707	0.6306	
SAM(HBP)	435.4006	0.001295	***
SAH(HBP)	538.6896	0.03282	**
MI(HBP)	0.7906479	0.0001276	****
SAM(Heart_diseases)	394.0012	0.0002738	****
SAH(Heart_diseases)	583.9596	0.4597	
MI(Heart_diseases)	0.7189607	8.612e-05	****
SAM(Inflammation)	554.6392	0.3228	
SAH(Inflammation)	651.8661	0.61	
MI(Inflammation)	0.9227298	0.002366	***
SAM(Kidney_diseases)	507.8832	0.2275	
SAH(Kidney_diseases)	638.395	0.8118	
MI(Kidney_diseases)	0.7567159	0.0001006	****
SAM(Liver_diseases)	550.6897	0.05257	*
SAH(Liver_diseases)	624.0728	0.9643	
MI(Liver_diseases)	1.005925	0.004219	***
SAM(Others)	473.3247	0.05172	*
SAH(Others)	528.8568	0.09604	*
MI(Others)	1.056442	0.04746	**
SAM(Sub_healthy)	616.6034	0.8935	
SAH(Sub_healthy)	487.1439	0.000455	****
MI(Sub_healthy)	2.067991	0.2305	